Abbott Laboratories (ABT.N)
69.03USD
6:53pm GMT
$-0.03 (-0.04%)
$69.06
$69.35
$69.69
$68.26
471,397
1,655,769
$74.15
$54.32
About
Overall
| Beta: | 1.57 |
| Market Cap(Mil.): | $95,559.38 |
| Shares Outstanding(Mil.): | 1,737.44 |
| Dividend: | 0.26 |
| Yield (%): | 1.93 |
Financials
| ABT.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 84.45 | 32.19 | 33.60 |
| EPS (TTM): | 0.65 | -- | -- |
| ROI: | 2.24 | 13.77 | 15.05 |
| ROE: | 4.07 | 16.51 | 16.62 |
Abbott, AbbVie settle TriCor marketing case for $25 million
Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.
UPDATE 2-Abbott, AbbVie settle TriCor marketing case for $25 mln
Oct 26 Abbott Laboratories and AbbVie Inc will pay a total of $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.
Abbott, AbbVie settle U.S. case over TriCor marketing for $25 mln
Oct 26 Abbott Laboratories and AbbVie Inc will pay $25 million to resolve allegations that Abbott paid kickbacks to doctors in exchange for them prescribing the cholesterol drug TriCor and promoted the medication for unapproved purposes.
Abbott Labs quarterly profit falls on higher tax expense
Abbott Laboratories reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.
UPDATE 1-Abbott Labs quarterly profit falls on higher tax expense
Oct 17 Abbott Laboratories reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.
Abbott Labs quarterly profit falls 6.6 pct on tax expense
Oct 17 Diversified healthcare company Abbott Laboratories reported a 6.6 percent drop in quarterly profit on Wednesday, hurt by higher tax expense on earnings.
Abbott Labs raises 2018 earnings forecast, shares hit record high
Abbott Laboratories raised its full-year earnings forecast and topped estimates for quarterly profit on Wednesday, powered by demand for its glucose monitoring device for diabetics and gains from its multibillion dollar acquisitions.
UPDATE 2-Abbott Labs raises 2018 earnings forecast, shares hit record high
* Shares hit record high (Adds details from conference call, analysts' quotes, updates shares)
Abbott Labs tops profit estimates, raises full-year earnings forecast
July 18 Abbott Laboratories raised its full-year earnings forecast and reported a quarterly profit that beat analysts' estimates, powered by higher sales across its businesses, including its top-earning medical device unit.
Allergan appoints former Abbott executive to its board
Allergan Plc said on Thursday former Abbott Laboratories executive Thomas Freyman will join its board, a week after two of its shareholders criticized the drugmaker's acquisition strategy and board composition.
Estimates